NVS - Better Coronavirus Stock: Grifols or Novartis?
Since the COVID-19 pandemic swept the world, healthcare stocks have been hotly traded in the face of turbulent and unpredictable market conditions. Whether investors are interested in speculating on price movements spurred by COVID-19 drug and vaccine development or simply chasing reliable earnings growth stemming from diagnostic-test production, there's something for everyone.
The Swiss pharma giant Novartis (NYSE: NVS) and the lesser-known Spanish multinational Grifols (NASDAQ: GRFS), which specializes in therapies based on blood plasma, are two competitors in this new and growing market of COVID-19 products. Given that Novartis' market cap of $196.4 billion is more than 10 times Grifols' $18.5 billion or so, how should potential buyers approach the question of which company warrants investment?
Image source: Getty Images.